Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.61−0.06 (-8.25%)
Close on Nov 13, 2026Market cap $354.83KP/E –Yield –
Virax Biolabs enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Virax Biolabs's enterprise value was -$6.32M on Nov 11, 2026, against -$2.71M a year earlier. Over the last 4 years it ranged from -$8.60M to $53.63M, with a median of -$1.83M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$6.32M | – |
| 2025 | Dec 31, 2025 | -$2.96M | -250.0% |
| 2024 | Dec 31, 2024 | $1.97M | – |
| 2023 | Dec 29, 2023 | -$7.31M | -203.8% |
| 2022 | Dec 30, 2022 | $7.04M | – |
See a number that looks wrong?